Esther Martinborough Increases Stake in Codexis, Inc.

Insider Esther Martinborough acquired 66,350 shares of Codexis, Inc. on June 17.

Written by EarningsIQ · Published Jun 19, 2026, 3:01 AM EDT · Updated Jun 20, 2026, 7:00 AM EDT

Key Points

Esther Martinborough purchased 66,350 shares of Codexis, Inc. on June 17, 2026, as part of recent insider activity.
Codexis, Inc. trades on the NasdaqGS at $2.57, with a market cap of $233.6 million and a 52-week range of $0.96 to $3.87.
Analysts from firms like Cantor Fitzgerald and Piper Sandler have reiterated buy ratings with price targets up to $11.00.

Esther Martinborough recently acquired 66,350 shares of Codexis, Inc. (NasdaqGS: CDXS) on June 17, 2026. This insider purchase adds to the ongoing activity within the company as it navigates its position in the biotechnology sector.

Insider Buying and Selling at Codexis, Inc.

On June 17, 2026, several insiders, including Esther Martinborough, acquired 66,350 shares each of Codexis, Inc. This increase in insider ownership comes at a time when Codexis is focusing on its proprietary enzyme technology solutions.

Other Institutional Activity in Codexis, Inc.

Several institutional investors have also made moves with Codexis shares. Aberdeen Group PLC increased its holdings by 713,870 shares, ending with 8,680,368 shares valued at about $14.1 million. Meanwhile, BlackRock, Inc. reduced its position by 366,967 shares, leaving it with 7,028,773 shares worth approximately $11.5 million. Opaleye Management Inc. made a slight reduction of 4,738 shares, maintaining 6,785,000 shares valued at $11.1 million. Nantahala Capital Management, LLC added 133,444 shares to hold 4,123,613 shares at a value of $6.7 million. Lastly, Millennium Management LLC increased its stake by 862,938 shares, bringing its total to 3,998,130 shares worth $6.5 million.

Codexis, Inc. Stock Snapshot

Shares of Codexis, Inc. (NasdaqGS: CDXS) are trading around $2.57. The company has a market cap of about $233.6 million. It operates with a beta of 2.478, indicating higher volatility compared to the market. The stock's 52-week range is between $0.96 and $3.87, with a 50-day moving average of $2.569 and a 200-day moving average of $2.0225. Codexis has a current ratio of 5.364 and a quick ratio of 4.927, though it carries a debt-to-equity ratio of 168.624.

Recent Earnings

Codexis reported revenue of $78.1 million, showing slight growth. Despite this, the company has a negative net margin of 40.97% and a return on equity of -68.90%. The next earnings report is expected on August 12, 2026.

Analysts Set New Price Targets

Several analysts have reiterated their ratings for Codexis. On August 29, 2024, Cantor Fitzgerald reiterated a buy rating with a price target of $11.00. Stifel Nicolaus maintained a buy rating with a $5.00 target on May 20, 2024. Piper Sandler also reiterated a buy rating, setting a $10.00 target on April 26, 2024. The overall analyst consensus recommends buying, with a mean target price of $6.58 based on six opinions.

About Codexis, Inc.

Codexis, Inc. is a biotechnology company based in Redwood City, California, specializing in enzyme technology solutions for therapeutic manufacturing. Founded in 2002, the company uses its proprietary CodeEvolver platform to develop and commercialize novel enzymes. Codexis works across various regions, including North America, Europe, and Asia, and holds partnerships with companies like Aldevron LLC and Pfizer Inc. Dr. Alison Moore serves as the CEO, leading a team of 146 employees.

Bottom Line

Esther Martinborough's recent purchase of Codexis shares highlights ongoing insider activity. Investors often watch such movements for potential signals about a company's prospects. Codexis, with its focus on enzyme technologies and strategic partnerships, continues to attract attention from both insiders and institutional investors. As always, remember that insider transactions are just one piece of the puzzle and should be considered alongside other factors when evaluating a stock.